Canine parvovirus (CPV) virus-like particle (VLP) vaccines and uses thereof
AssigneeBoehringer Ingelheim Animal Health USA Inc.
InventorsFrederic David, Zahia Hannas-Djebbara, Herve Poulet, Jules Maarten Minke
Life of this patent
Estimating the term…
Abstract
The present disclosure encompasses canine parvovirus (CPV) vaccines or compositions. The vaccine or composition may be a vaccine or composition containing CPV virus-like particle (VLP), and a preparation method and a use thereof. The CPV VLPs are formed by the CPV VP2 protein. Further, the disclosure broadly encompasses vaccines comprising combinations of MLV and VLP, which are capable of overcoming MDA against a variety of pathogens, which infect a variety of different species.
Claims17
A vaccine capable of inducing a protective immune response against canine parvovirus (CPV) in canines with maternally derived antibodies (MDAs) to CPV, comprising:
- a canine parvovirus modified-live virus (CPV MLV);
- and
- canine parvovirus virus-like particles (CPV VLPs) in an amount effective to overcome a neutralizing effect of MDAs against CPV in canines with MDAs to CPV.
A plasmid configured to produce, when expressed, a canine parvovirus virus-like particle (CPV VLP) comprising a canine parvovirus (CPV) antigenic polypeptide having 90% or greater sequence identity to at least one of SEQ ID NOs:
- 1, 3, 4, 6, 8, 9, and 10.
A method for eliciting a protective immune response against canine parvovirus (CPV) in a canine comprising administering to the canine a canine parvovirus modified-live virus (CPV MLV) and canine parvovirus virus-like particles (CPV VLPs) in an amount effective to overcome a neutralizing effect of maternally derived antibodies (MDAs) against CPV in canines with MDAs to CPV.
Dependencies are inferred from the claim text.